Japan Cell Therapy Market -2024-2031

Japan Cell Therapy Market -2024-2031

Japan Cell Therapy Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

The Japan market for cell therapy is constantly growing to include new cell types, which presents significant opportunities for companies to strengthen their market positions. As a result, during the past few years, there has been a dramatic increase in the number of companies engaged in developing cell therapies.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of cancers in Japan

CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them to locate in destroy cancer cells more effectively. In Japan, cancer has been the leading cause of death since 1981, accounting for one-third of total deaths in this developed country with a high life expectancy.

According to the National Cancer Center of Japan, there were estimations of 1,019,000 new cancer cases and 380,400 cancer deaths in 2022. The most common cancers in Japan include colorectal, stomach, lung, prostate, and female breast cancers, which account for approximately 60% of all cancer cases in the country.

Furthermore, Japan cell therapy is also driven by various other factors like a rise in the advancements in the equipment, novel product launches by key players and others helping the market to grow during the forecast period.

Dearth of skilled professionals

Despite technological advancements and product development over the last decade, the market has been hampered by a shortage of skilled workers who can operate sophisticated instruments like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are technologically modern and very complicated, produce a wide range of data outputs that require skill to analyse and review. There remains, nevertheless, a global demand-supply gap for trained people.

For more details on this report – Request for Sample

Segment Analysis

The Japan cell therapy market is segmented based on product type, process, application, end-user and region.

The equipment from the product type segment accounted for approximately 41.7 % of the Japan cell therapy market share

The equipment from the product type segment accounted for approximately 41.7%. Cell therapy involves the use of various equipment, including biosafety cabinets, incubators, refrigerators, freezers, centrifuges, bioreactors, microscopes, and cell counters. These cabinets provide a controlled environment for working with materials that require specific protection. Incubators maintain optimal conditions for cell growth and proliferation.

Refrigerators store materials at specific temperatures, while freezers store cells, tissues, and biological samples for long-term storage. Centrifuges separate components based on density. Other equipment like bioreactors, microscopes, and cell counters are also commonly used. Companies like Corning provide specialised equipment for cell and gene therapy applications that meet FDA standards.

For instance, in February 2022, Takara Bio Inc. opened an expansion of its manufacturing facility, the Center for Gene and Cell Processing (CGCP), at the company’s headquarters in Shiga, Japan. The expansion of the facility, which went into operation in 2020, features increased production capacity. New equipment includes 200 L bioreactors, 2,000 L fermenters, and large flow centrifuge and purification systems.

Covid 19 Impact Analysis

The impact of COVID-19 on cell therapy in Japan has been significant, affecting various aspects of healthcare and treatment. Studies have shown that the pandemic has disrupted the cell and gene therapy industry globally, including Japan. Specifically, the pandemic has influenced allogeneic stem cell transplantation in Japan, affecting healthcare quality and access for patients undergoing these procedures.

Market Segmentation

By Product Type
• Equipment
Cell Processing Equipment
Single-Use Equipment
Others
• Software
• Consumables

By Process
• Cell Processing
• Cell Preservation, Distribution, and Handling
• Process Monitoring and Quality Control

By Application
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Urinary Disorders
• Others

By End User
• Hospitals
• Clinics
• Others

Competitive Landscape

The major global players in the market include Fresenius Kabi, Thermo Fisher Scientific, Inc., Terumo Corporation, Stemcell Technologies, Sartorius, Aurion Biotech, Novartis AG, JCR Pharmaceuticals Co., Ltd, Johnson & Johnson Services, Inc. and among others.

Key Developments

 In March 2023, Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel cell therapy Vyznova for the treatment of bullous keratopathy of the cornea.

Why Purchase the Report?
• To visualize the Japan cell therapy market segmentation based on product type, process, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of Japan cell therapy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Japan cell therapy market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies